Jaya Goswami, MD

Sr. Director, Clinical Development Lead, ID Development
Moderna, Inc.

Disclosure(s): Moderna, Inc.: Employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-97) Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an Investigational Vaccine Against RSV, Given at 12 Months Following a Primary Dose in Adults Aged ≥ 50 Years
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT